Home
Shenzhen Taji Rui Biological Pharmace...

Shenzhen Taji Rui Biolog... Market Share Analysis for June 2026

塔吉瑞

Industry: N/A

Domaintjrbiosciences.com

Year Founded2014

Employees51 - 200

Annual Revenue--

Shenzhen Taji Rui Biological Pharmace...

Shenzhen Taji Rui Biological Pharmace... (including company regionals)

tjrbiosciences.com

See more website traffic and engagement information

Total visits to Shenzhen Taji Rui Biological Pharmace...'s top domains

Understand Shenzhen Taji Rui Biological Pharmace... market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

tjrbiosciences.com239

See more with Sales Intelligence

Avg. visit duration in Shenzhen Taji Rui Biological Pharmace...'s top domains

Analyze Shenzhen Taji Rui Biological Pharmace... engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

tjrbiosciences.com00:00:57

See more with Sales Intelligence

Avg. pageviews on Shenzhen Taji Rui Biological Pharmace...'s top domains

See how Shenzhen Taji Rui Biological Pharmace... keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

tjrbiosciences.com2.39

See more with Sales Intelligence

Shenzhen Taji Rui Biological Pharmace... top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Shenzhen Taji Rui Biological Pharmace...

These are the website technologies, by industry, used by Shenzhen Taji Rui Biological Pharmace... top domains

Mobile (3)

Meta Viewport

Widget (2)

Baidu Maps

Advertising (1)

PubMatic

Content Management System (1)

WordPress

More Technologies

1

See all

News & Signals from Shenzhen Taji Rui Biological Pharmace...

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsTjrbiosciences receives financing of $50M in Series C.Sino-American oncology company Shenzhen TargetRx has successfully completed its Series C financing, raising $50 million.